Pembrolizumab for abnormal mouth patches that may become cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies pembrolizumab (an immune medicine) for leukoplakia and related abnormal mouth patches with moderate/severe pre-cancer changes. It aims to see whether the treatment can shrink or control the lesions when surgery or radiation isn’t an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have leukoplakia, erythroleukoplakia, or proliferative verrucous leukoplakia with visible spots that can be measured in two directions.
- Your lesions can’t be fully treated with surgery or radiation, or you’ve already refused those treatments—and at least one lesion can be followed during treatment.
- Your biopsy shows moderate or severe dysplasia or carcinoma in situ (serious pre-cancer changes).
- You can provide a biopsy sample and agree to more biopsies at about 6 months, plus allow photos of the lesions.
- Your overall health/lab tests must be sufficient (blood counts, kidney/liver tests) and you should not be very frail (ECOG performance status 0–1).
- If you could become pregnant (or someone could become pregnant via you), you must use reliable birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests pembrolizumab (an immune treatment) to see if it can treat high-grade abnormal cells of the cervix (CIN 2/3 or carcinoma in situ). You may need biopsies during the study and a planned procedure after about 24 weeks to remove or sample the cervix tissue.
This trial tests whether giving a type of radiation therapy (proton or photon) along with the immunotherapy drug pembrolizumab before surgery is safe and effective for people with certain oral cavity cancers. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
This Phase 2 trial tests pembrolizumab (an immune therapy) plus low-dose oral cyclophosphamide in people with chest wall breast cancer that has spread locally and may have distant metastases. It aims to see if this combination can shrink tumors and control cancer longer, especially in tumors with certain immune markers.
This trial studies whether a two-medicine diabetes drug combination can reduce or control risky early changes in certain mouth and throat lesions. You may be asked for small tissue samples (biopsies) before and after 12 weeks to see how the lesions respond.
Hear when a new Leukoplakia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.